Hematologic Cancers | Data + Perspectives: Investigators Discuss the Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with Hematologic Cancers

Featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, including the following topics:

• Part 1: Case Presentations and Clinical Decision-Making (0:00)
• Case: A man in his early 70s with diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma — Ian W Flinn, MD, PhD (3:46)
• Case: A man in his late 50s with nongerminal center B-cell-like subtype DLBCL — Laurie H Sehn, MD, MPH (15:57)
• Case: CAR-T therapy during the pandemic — Nikhil C Munshi, MD (22:16)
• Case: Anti-BCMC bispecific in triple-class and penta-drug refractory disease — Ajai Chari, MD (33:54)
• CAR-T therapy for non-Hodgkin lymphoma — Dr Flinn (37:09)
• Bispecifics for non-Hodgkin lymphoma — Dr Sehn (51:48)
• CAR-T therapy for multiple myeloma — Dr Munshi (1:13:23)
• Bispecifics for multiple myeloma — Dr Chari (1:26:14)

CME information and select publications